FMGE pharmacology questions

Phenytoin shows dose-dependent (zero order) elimination once its metabolizing enzymes become saturated, so a constant amount rather than a constant fraction is eliminated per unit time. This causes a disproportionate, unpredictable rise in plasma concentration with small dose increments near the saturation point. Ethanol and high-dose aspirin behave similarly once hepatic enzyme capacity is saturated. In zero order kinetics the half-life is not constant and increases with dose, unlike first order kinetics where a constant fraction is eliminated per unit time.

• A. Facilitated diffusion describes a transport mechanism, not a pattern of drug elimination kinetics.
• C. In first order kinetics a constant fraction of drug is eliminated per unit time, giving a predictable, proportional rise in concentration, not a disproportionate one.
• D. Phenytoin shows zero order kinetics specifically at therapeutic to toxic doses once enzymes saturate, not only at low doses; this option reverses the concept.

Loading dose is calculated as Vd × target plasma concentration, where Vd is first expressed in absolute volume (L) by multiplying Vd per kg by body weight. Here Vd = 0.7 L/kg × 60 kg = 42 L, and loading dose = 42 L × 20 mg/L = 840 mg. This formula gives the dose required to rapidly achieve a desired steady plasma concentration, independent of elimination half-life. Loading dose calculations assume the drug distributes into the volume of distribution before significant elimination occurs.

• A. This value results from using body weight directly without multiplying by Vd per kg correctly to get total body Vd.
• B. This underestimates the dose by using an incorrect Vd value in the calculation.
• C. This overestimates the dose and does not match Vd × target concentration for the given parameters.

Drugs absorbed orally pass through the portal circulation and liver before reaching systemic circulation, where extensive hepatic metabolism (first pass effect) can inactivate much of the dose before it reaches the target tissues. Sublingual and buccal absorption drain into systemic veins (via the lingual and facial veins), bypassing the portal vein and liver entirely, so a much larger fraction of the dose reaches systemic circulation intact. This explains why drugs with high first pass metabolism, such as nitroglycerin, are given sublingually. Plasma protein binding and renal clearance occur after a drug has already reached systemic circulation and do not explain differences in bioavailability by route.

• A. Renal clearance occurs after the drug reaches systemic circulation and does not depend on the route of administration.
• B. Protein binding affects free drug concentration in plasma, not the fraction of dose entering systemic circulation after absorption.
• C. Gastric acid degradation is a separate issue from first pass metabolism and is not the primary reason for the described difference.

Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes (particularly CYP3A4), which increases the metabolism of estrogen and progestin components of combined oral contraceptives. This lowers their plasma concentration below the level needed for reliable ovulation suppression, leading to contraceptive failure. Women on rifampicin-containing regimens should be advised to use additional or alternative contraceptive methods. This is a classic pharmacokinetic drug interaction tested because of its clinical relevance in tuberculosis-endemic settings like India.

• B. Rifampicin does not significantly impair intestinal absorption of oral contraceptive steroids.
• C. Plasma protein displacement is not the mechanism of this interaction; enzyme induction accelerating metabolism is.
• D. Rifampicin does not primarily act by increasing renal excretion of steroid hormones.

Erythromycin and other macrolides are known inhibitors of hepatic cytochrome P450 enzymes (CYP3A4), which reduces the metabolic clearance of warfarin and leads to accumulation of the anticoagulant. This raises INR substantially above the therapeutic range and increases bleeding risk, as seen with the gum bleeding in this patient. Clinicians should anticipate this interaction and either choose a non-interacting antibiotic or closely monitor INR with dose adjustment. Enzyme induction, protein displacement, and effects on gut flora are not the mechanism of this particular interaction.

• A. Protein binding displacement would cause only a transient rise in free drug level, not the sustained marked INR elevation seen with enzyme inhibition.
• B. Increased vitamin K synthesis would lower, not raise, the INR, and macrolides do not act through this mechanism.
• C. Enzyme induction would decrease, not increase, warfarin's anticoagulant effect by enhancing its clearance.

Competitive antagonists bind reversibly to the same receptor site as the agonist and can be displaced by increasing the agonist concentration, producing a parallel rightward shift of the dose-response curve with unchanged maximum response (Emax). This is in contrast to non-competitive or irreversible antagonists, which reduce the maximum response achievable because they cannot be overcome by raising agonist concentration. Physiological antagonism occurs when two agonists act on different receptors to produce opposite physiological effects, not a shift of the same curve. The parallel shift with preserved Emax is the key distinguishing feature of competitive antagonism on a dose-response curve.

• A. Non-competitive antagonism reduces the maximum response (Emax) and does not allow a parallel shift with unchanged maximum.
• B. Irreversible antagonism typically reduces Emax because the antagonist cannot be displaced by increasing agonist concentration.
• D. Physiological antagonism involves two agonists acting on separate receptor systems with opposing effects, not displacement at a shared receptor.

Therapeutic index (TI) is the ratio of the toxic dose (commonly TD50) to the effective dose (ED50) of a drug. A low or narrow therapeutic index means the toxic and effective doses are close together, so a small increase in dose or plasma level can precipitate toxicity, as seen with drugs like digoxin, lithium, phenytoin, and warfarin. These drugs require therapeutic drug monitoring to maintain plasma levels within a safe and effective range. Potency and efficacy describe different pharmacological properties and do not by themselves indicate safety margin.

• A. Efficacy refers to the maximal effect a drug can produce, not the margin between therapeutic and toxic doses.
• B. The slope of the dose-response curve relates to the range over which dose changes affect response, not directly to the toxic-to-effective dose ratio.
• C. Potency refers to the dose required to produce a given effect, not the safety margin between effective and toxic doses.

Atropine competitively blocks muscarinic acetylcholine receptors, reversing the muscarinic effects of organophosphate poisoning such as bronchorrhea, bronchospasm, bradycardia, and excessive salivation. The endpoint of atropinization is clinical: drying of secretions, a clear chest on auscultation, heart rate above 80/min, and mild mydriasis, rather than a fixed dose target. Atropine has no effect on nicotinic receptors, so it does not improve skeletal muscle fasciculations or weakness, which require pralidoxime for reactivation of acetylcholinesterase. Over-atropinization causing coma or fixed dilated pupils with hyperthermia should be avoided and is a sign of toxicity, not an endpoint to aim for.

• B. Fasciculations are a nicotinic effect, which atropine does not reverse; pralidoxime is needed for this.
• C. Unresponsiveness and fixed dilated pupils suggest atropine toxicity, not the correct therapeutic endpoint.
• D. Pinpoint pupils and bradycardia are signs of ongoing muscarinic toxicity, not adequate atropinization.

Pralidoxime reactivates acetylcholinesterase inhibited by organophosphates by breaking the phosphate-enzyme bond, but only if given before the complex undergoes 'aging', a dealkylation reaction that strengthens the bond and makes it permanently resistant to hydrolysis. This is why pralidoxime must be given as early as possible, ideally within 24-36 hours of exposure. Pralidoxime is also ineffective against carbamate poisoning since carbamates inhibit cholinesterase by a different, non-aging mechanism. It has no significant action on muscarinic receptors; that effect is produced by atropine.

• B. Organophosphate excretion is not the mechanism responsible for aging of the enzyme-inhibitor complex
• C. Pralidoxime acts on acetylcholinesterase, not on muscarinic receptors; atropine blocks those receptors
• D. Pralidoxime itself is renally excreted, and this does not explain the time-dependent loss of efficacy on the enzyme complex

Metoprolol is a cardioselective beta-1 blocker that at standard doses has minimal effect on bronchial beta-2 receptors, making it safer than non-selective agents in patients with reactive airway disease. Propranolol, nadolol and timolol are all non-selective beta-blockers that block both beta-1 and beta-2 receptors and can precipitate bronchospasm in asthmatics. Even cardioselective agents should be used cautiously and at the lowest effective dose in asthma, since selectivity is relative and lost at higher doses. Atenolol is another beta-1 selective agent commonly used in such patients.

• A. Nadolol is a non-selective beta-blocker and is not preferred in asthma
• B. Timolol is non-selective and is better known for its use in glaucoma and its systemic beta-2 blocking effects
• D. Propranolol is non-selective and blocks beta-2 receptors, risking bronchospasm in asthmatics

Phenoxybenzamine is a long-acting, irreversible non-selective alpha blocker that is started 10-14 days before surgery to control catecholamine-induced hypertension and allow re-expansion of the chronically contracted intravascular volume. Adequate alpha blockade must always precede beta blockade in pheochromocytoma, because beta blockade alone would leave alpha-mediated vasoconstriction unopposed and could worsen hypertension. Diuretics are avoided since patients are typically volume-depleted, and ACE inhibitors are not the standard preoperative agents for this condition. Phenoxybenzamine also reduces the risk of a hypertensive crisis during tumor handling intraoperatively.

• A. Beta blockers must never be given before adequate alpha blockade in pheochromocytoma, as this can cause unopposed alpha-mediated hypertensive crisis
• B. ACE inhibitors are not the standard preoperative drug for controlling catecholamine excess in pheochromocytoma
• C. Diuretics are avoided since these patients are usually volume-contracted, not volume-overloaded

Beta-2 agonists like salbutamol stimulate beta-2 receptors on skeletal muscle and liver cells, activating Na+-K+-ATPase pumps via a cAMP-mediated pathway and driving potassium from the extracellular space into cells, lowering serum potassium without any net loss from the body. The same beta-2 mediated effect on skeletal muscle causes fine tremors, a common dose-related adverse effect. This intracellular shift of potassium is the same principle used therapeutically when salbutamol nebulization is used as emergency treatment for hyperkalemia. Renal excretion, sweating and aldosterone are not involved in this acute shift.

• A. Sweating is not a recognized mechanism for salbutamol-induced hypokalemia
• B. Salbutamol does not act through inhibition of aldosterone secretion
• D. Salbutamol does not act primarily by increasing renal potassium excretion in this acute setting

Ketamine produces dissociative anesthesia by non-competitively antagonizing NMDA glutamate receptors in the cortex and limbic system, functionally dissociating the thalamocortical and limbic systems so the patient appears awake with open eyes and nystagmus but is unresponsive to pain and unaware of surroundings. Unlike most intravenous anesthetics, ketamine stimulates the sympathetic nervous system, increasing heart rate, blood pressure and cardiac output, which makes it useful in hypovolemic or hypotensive trauma patients. GABA-A agonism is the mechanism of barbiturates, benzodiazepines and propofol, not ketamine. Ketamine is not a sodium channel blocker or an opioid receptor agonist.

• A. GABA-A agonism is the mechanism of propofol, barbiturates and benzodiazepines, which produce sedation without dissociation
• C. Opioid receptor agonism describes analgesics like morphine, not the dissociative action of ketamine
• D. Sodium channel blockade is the mechanism of local anesthetics, not ketamine

This presentation is classic for malignant hyperthermia, a hypermetabolic crisis triggered in genetically susceptible individuals by volatile anesthetics like halothane and depolarizing muscle relaxants like succinylcholine, caused by uncontrolled calcium release from the sarcoplasmic reticulum via the ryanodine receptor. Dantrolene is the specific treatment; it blocks ryanodine receptor-mediated calcium release from the sarcoplasmic reticulum, reducing muscle rigidity and hypermetabolism. The triggering anesthetic must also be stopped immediately and the patient actively cooled. Flumazenil and naloxone reverse benzodiazepine and opioid effects respectively and are irrelevant here, while neostigmine is a cholinesterase inhibitor used to reverse non-depolarizing neuromuscular blockade.

• A. Flumazenil is a benzodiazepine antagonist and has no role in malignant hyperthermia
• B. Neostigmine reverses non-depolarizing muscle relaxants and has no role in this hypermetabolic crisis
• D. Naloxone reverses opioid effects and does not treat malignant hyperthermia

Adrenaline is added to local anesthetics to cause local vasoconstriction, reducing systemic absorption and prolonging duration of action, but in areas supplied by end-arteries with poor collateral circulation such as digits, nose, ear lobe and penis, this vasoconstriction can critically reduce blood flow and cause tissue ischemia or necrosis. For this reason, plain local anesthetic without adrenaline is used for nerve blocks at these sites. The vasoconstrictor effect actually decreases rather than increases systemic absorption, which is the opposite of what makes it dangerous here. Methemoglobinemia is a known risk of prilocaine and benzocaine, unrelated to adrenaline or to the anatomical site.

• A. Methemoglobinemia is associated with prilocaine or benzocaine toxicity, not with adrenaline
• C. Prolongation of action is a beneficial effect of adrenaline elsewhere and is not the reason it is avoided at end-arterial sites
• D. Adrenaline decreases, not increases, systemic absorption of local anesthetic by causing vasoconstriction

This patient shows the classic opioid toxicity triad of respiratory depression, miosis, and coma, most likely from heroin or morphine overdose. Naloxone is a competitive opioid receptor antagonist that rapidly reverses respiratory depression and CNS depression by displacing the opioid from mu receptors. It has a short half-life, so repeated doses or an infusion may be needed. It is the standard emergency antidote for opioid overdose.

• A. Atropine treats bradyarrhythmias and organophosphate poisoning, not opioid overdose.
• B. N-acetylcysteine is the antidote for paracetamol overdose.
• C. Flumazenil reverses benzodiazepine, not opioid, toxicity.

COX-1 is constitutively expressed in gastric mucosa and maintains the protective prostaglandin barrier, while COX-2 is induced at sites of inflammation. Celecoxib selectively inhibits COX-2 while sparing COX-1, reducing gastric prostaglandin depletion and lowering the risk of peptic ulceration and GI bleeding compared with non-selective NSAIDs. This selectivity comes at the cost of increased cardiovascular thrombotic risk because COX-2 inhibition reduces vascular prostacyclin without affecting platelet thromboxane. Celecoxib is useful in patients with high GI risk but should be used cautiously in those with cardiovascular disease.

• A. Ibuprofen is a non-selective COX inhibitor with significant GI toxicity.
• B. Indomethacin is a potent non-selective COX inhibitor with high GI toxicity.
• D. Aspirin irreversibly inhibits both COX-1 and COX-2 and is particularly ulcerogenic.

Valproate is well known for two major adverse effects: dose-independent hepatotoxicity, which can be fatal, especially in young children, and teratogenicity, with a significantly increased risk of neural tube defects such as spina bifida when taken during the first trimester. Because of this, valproate is avoided in women of childbearing age unless no safer alternative controls seizures, and folic acid supplementation is advised preconceptionally. Liver function tests and serum ammonia should be monitored during therapy. Valproate also inhibits hepatic drug metabolism, increasing levels of co-administered drugs.

• A. Phenobarbitone is associated with sedation and dependence, not primarily this hepatotoxicity-teratogenicity combination.
• B. Carbamazepine causes aplastic anemia and Stevens-Johnson syndrome but has a lower neural tube defect risk than valproate.
• C. Lamotrigine has a comparatively low teratogenic risk and is not typically hepatotoxic.

Phenytoin is classically associated with gingival hyperplasia due to its effect on fibroblast proliferation and collagen synthesis in gum tissue, seen with chronic use. It is also a well-recognized cause of severe cutaneous adverse reactions, including Stevens-Johnson syndrome, which presents with fever, mucosal involvement, and epidermal detachment affecting less than 10% of body surface area. Other phenytoin adverse effects include cerebellar signs like nystagmus and ataxia, hirsutism, and megaloblastic anemia from folate deficiency. Patients should be counseled on oral hygiene and warned about early rash symptoms.

• A. Sodium valproate causes hepatotoxicity and weight gain, not gingival hyperplasia or SJS classically.
• C. Gabapentin is associated with sedation and ataxia, not gingival hyperplasia or SJS.
• D. Ethosuximide is associated with GI upset and blood dyscrasias, not these findings.

This child's presentation of brief staring spells with eyelid fluttering and 3 Hz spike-and-wave discharges on EEG is classic for absence (petit mal) seizures. Ethosuximide is the drug of choice for absence seizures, acting by blocking T-type calcium channels in thalamic neurons that generate the 3 Hz rhythm. Sodium valproate is an effective alternative, particularly if the child also has generalized tonic-clonic seizures. Drugs like phenytoin and carbamazepine are contraindicated as they can worsen absence seizures.

• A. Carbamazepine can worsen absence seizures and is not used for this indication.
• B. Phenobarbitone is not first-line for absence seizures and is more sedating.
• C. Phenytoin is ineffective for absence seizures and can actually exacerbate them.

Lithium is handled by the kidney similarly to sodium, being freely filtered and reabsorbed mainly in the proximal tubule. Thiazide diuretics cause volume depletion and compensatory increased sodium and water reabsorption in the proximal tubule, which drags lithium along with it, raising serum lithium levels and precipitating toxicity. This presents with coarse tremor, ataxia, dysarthria, vomiting, and in severe cases seizures and coma. Lithium levels and renal function should be closely monitored whenever diuretics, NSAIDs, or ACE inhibitors are co-administered.

• B. Lithium is not significantly protein-bound, so this mechanism is not relevant.
• C. Lithium is not hepatically metabolized; it is excreted unchanged by the kidney.
• D. Thiazides do not act on gut absorption of lithium; the interaction is renal.

This patient has drug-induced parkinsonism, a common extrapyramidal side effect of typical antipsychotics like haloperidol, caused by dopamine D2 receptor blockade in the nigrostriatal pathway. This creates a relative cholinergic excess in the striatum, so a centrally acting anticholinergic such as trihexyphenidyl restores the dopamine-acetylcholine balance and relieves rigidity, bradykinesia, and tremor. Other extrapyramidal syndromes from antipsychotics include acute dystonia, akathisia, and tardive dyskinesia, each with different management. Anticholinergics are not useful for tardive dyskinesia, which may actually worsen with them.

• A. Lorazepam may help acute dystonia or akathisia but does not directly address this cholinergic-dopaminergic imbalance.
• B. Propranolol is used for akathisia, not drug-induced parkinsonism.
• D. Bromocriptine is a dopamine agonist used in neuroleptic malignant syndrome, not routine drug-induced parkinsonism.

This presentation represents anaphylaxis, a type I IgE-mediated hypersensitivity reaction triggered by penicillin, which acts by binding penicillin-binding proteins to inhibit bacterial cell wall transpeptidation. Adrenaline given intramuscularly is the first-line drug in anaphylaxis because it reverses hypotension and bronchospasm via alpha-1 and beta-2 adrenergic receptor stimulation and prevents further mediator release through beta-2 mediated mast cell stabilization. Corticosteroids and antihistamines are useful adjuncts but act too slowly to be life-saving in the acute phase. Nebulized bronchodilators help bronchospasm alone but do not address hypotension.

• B. Hydrocortisone has a delayed onset of action and is an adjunct, not the immediate life-saving drug.
• C. Antihistamines have slow onset and do not reverse hypotension or severe bronchospasm.
• D. Salbutamol nebulization addresses bronchospasm only and does not correct hypotension.

Ceftriaxone is a third-generation cephalosporin with high lipid solubility and low protein binding at inflamed meninges, allowing it to achieve therapeutic concentrations in cerebrospinal fluid, making it the empirical drug of choice for bacterial meningitis in adults and children beyond the neonatal period. It covers the common causative organisms including Streptococcus pneumoniae and Neisseria meningitidis. Cefuroxime, though a cephalosporin, has inferior CSF penetration and is not preferred for meningitis. Amoxicillin and cephalexin do not achieve adequate CSF levels and are not used as monotherapy for bacterial meningitis.

• A. Cefuroxime has poor CSF penetration compared to third-generation cephalosporins and is not used for meningitis.
• B. Amoxicillin alone does not achieve reliable CSF levels against the likely pathogens and is not standard empirical therapy.
• D. Cephalexin is an oral first-generation cephalosporin with negligible CSF penetration, unsuitable for meningitis.

Aminoglycosides such as gentamicin are actively taken up and concentrated in renal proximal tubular cells and in the hair cells of the cochlea and vestibular apparatus, causing dose- and duration-dependent nephrotoxicity and ototoxicity. This cellular accumulation leads to oxidative damage and cell death, which is why trough drug levels, serum creatinine, and audiometry are monitored during therapy. The nephrotoxicity is typically reversible while ototoxicity can be permanent. Unlike beta-lactams, aminoglycoside renal injury is not primarily immune-mediated.

• A. Crystalluria causing renal injury is seen with drugs like sulfonamides and acyclovir, not aminoglycosides.
• C. Immune-mediated interstitial nephritis with eosinophilia is typical of beta-lactams like methicillin, not aminoglycosides.
• D. Bone marrow suppression is characteristic of chloramphenicol, not aminoglycosides.

Tetracyclines such as doxycycline chelate calcium and are deposited in developing teeth and bones, causing permanent discoloration of deciduous teeth and inhibition of bone growth in the fetus and in young children. For this reason, tetracyclines are contraindicated during pregnancy and in children under eight years of age. Amoxicillin and cephalexin are beta-lactams considered safe in pregnancy. Nitrofurantoin is commonly used for urinary tract infections in pregnancy, though it is avoided near term due to the risk of neonatal hemolysis.

• A. Cephalexin is a cephalosporin generally considered safe throughout pregnancy.
• B. Amoxicillin is a beta-lactam generally considered safe throughout pregnancy.
• D. Nitrofurantoin is commonly used for urinary tract infections in pregnancy outside of the late third trimester.

Gray baby syndrome occurs in neonates, particularly premature infants, given chloramphenicol because they have immature hepatic glucuronyl transferase activity and reduced renal excretion, leading to drug accumulation that causes cardiovascular collapse, cyanosis, and the characteristic ashen-gray skin color. Chloramphenicol also causes dose-independent idiosyncratic aplastic anemia in any age group through bone marrow stem cell injury. Ceftriaxone is additionally avoided in neonates due to risk of biliary sludging and kernicterus from bilirubin displacement, but it does not cause gray baby syndrome. Gentamicin and vancomycin are not associated with this presentation.

• A. Vancomycin causes red man syndrome and nephrotoxicity, not gray baby syndrome.
• B. Ceftriaxone is avoided in neonates due to kernicterus risk, not gray baby syndrome.
• D. Gentamicin causes nephrotoxicity and ototoxicity, not gray baby syndrome.

Cotrimoxazole (trimethoprim-sulfamethoxazole) is the first-line agent for primary prophylaxis against Pneumocystis jirovecii pneumonia in HIV-infected patients once the CD4 count falls below 200 cells/microL. It combines inhibition of dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in the organism. Prophylaxis is continued until the CD4 count rises above 200 cells/microL for at least three months on antiretroviral therapy. Cotrimoxazole also provides cross-protection against toxoplasmosis and some bacterial infections.

• A. Dapsone is a second-line alternative for Pneumocystis prophylaxis in patients who cannot tolerate cotrimoxazole.
• B. Azithromycin is used for prophylaxis against Mycobacterium avium complex, not Pneumocystis jirovecii.
• C. Fluconazole is an antifungal used for candidiasis or cryptococcal disease prophylaxis, not Pneumocystis pneumonia.

Vancomycin remains the standard first-line drug for serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) with preserved vancomycin susceptibility. It acts by inhibiting bacterial cell wall synthesis through binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, a site unaffected by the mecA-mediated resistance that causes methicillin resistance. Linezolid is an alternative, particularly for skin and soft tissue infections or when nephrotoxicity is a concern, but vancomycin is the conventional first choice. Serum trough levels should be monitored to balance efficacy and nephrotoxicity.

• A. Cefazolin is a beta-lactam used for methicillin-sensitive Staphylococcus aureus, not MRSA.
• B. Amoxicillin-clavulanate is a beta-lactam combination and does not overcome MRSA resistance.
• D. Ceftriaxone, a beta-lactam, is ineffective against MRSA because the mecA gene alters penicillin-binding protein affinity for all beta-lactams.

Isoniazid causes peripheral neuropathy by increasing renal excretion of pyridoxine and forming a hydrazone complex with pyridoxal phosphate, depleting the active cofactor needed for neurotransmitter and myelin synthesis. This risk is higher in slow acetylators, malnourished patients, alcoholics, diabetics, and pregnant women. Prophylactic pyridoxine, typically 10 mg daily, is given with isoniazid in high-risk patients to prevent this adverse effect. Established neuropathy is treated with higher doses of pyridoxine, around 100 mg daily.

• A. Folic acid deficiency causes megaloblastic anemia, not peripheral neuropathy from isoniazid.
• B. Thiamine deficiency causes Wernicke-Korsakoff syndrome and beriberi, unrelated to isoniazid's mechanism of neuropathy.
• D. Vitamin B12 deficiency causes subacute combined degeneration, not the mechanism underlying isoniazid-induced neuropathy.

Rifampicin is excreted in body secretions and imparts a harmless orange-red discoloration to urine, tears, sweat and contact lenses, which patients should be counseled about before starting therapy to prevent unnecessary alarm or non-compliance. This finding does not indicate toxicity and requires no change in therapy. Rifampicin can separately cause hepatotoxicity and induces hepatic cytochrome P450 enzymes, but this is monitored through liver function tests and clinical symptoms such as jaundice or vomiting, not by the color of secretions. In this asymptomatic patient with normal liver function tests, reassurance is sufficient.

• B. Stopping the drug is unwarranted since red-orange discoloration is an expected, harmless finding, not a sign of toxicity.
• C. Liver biopsy is invasive and unnecessary when liver function tests are normal and the patient is asymptomatic.
• D. Dose reduction is not indicated for a harmless pigmentary change unrelated to drug efficacy or toxicity.

Ethambutol causes dose-dependent optic neuritis, classically presenting with loss of red-green color discrimination and decreased visual acuity due to its action on retinal ganglion cells and the optic nerve, possibly through chelation of metal ions needed for mitochondrial function. Patients should undergo baseline and periodic visual acuity and color vision testing while on ethambutol, and the drug must be stopped immediately if visual symptoms develop, as changes are usually reversible if caught early. Ethambutol is generally avoided or used cautiously in young children who cannot reliably report visual symptoms. Recovery of vision occurs gradually after drug withdrawal.

• B. Isoniazid causes peripheral neuropathy and hepatotoxicity, not optic neuritis.
• C. Pyrazinamide causes hyperuricemia and hepatotoxicity, not optic nerve toxicity.
• D. Rifampicin causes hepatotoxicity and orange body secretions, not visual color discrimination defects.

Pyrazinamide inhibits renal tubular secretion of uric acid, leading to hyperuricemia that can precipitate acute gouty arthritis, classically affecting the first metatarsophalangeal joint as seen in this patient. Pyrazinamide is also one of the more hepatotoxic first-line antitubercular drugs and requires monitoring of liver function during therapy. Hyperuricemia from pyrazinamide is usually asymptomatic but should be watched for in patients with pre-existing gout or renal impairment. Symptomatic hyperuricemia can be managed with NSAIDs for the acute attack while continuing therapy if clinically required, though severe cases may need dose adjustment.

• B. Streptomycin causes ototoxicity and nephrotoxicity, not hyperuricemia.
• C. Ethambutol is associated with optic neuritis and is not a recognized cause of hyperuricemia.
• D. Isoniazid causes hepatotoxicity and peripheral neuropathy, not hyperuricemia or gout.

Acyclovir is a guanosine analogue that is monophosphorylated by herpes simplex virus-encoded thymidine kinase, an enzyme far more efficient at phosphorylating acyclovir than the host cellular enzyme. Host cell kinases then convert it to acyclovir diphosphate and triphosphate. Acyclovir triphosphate inhibits viral DNA polymerase and causes chain termination after incorporation into viral DNA. This selective first-step activation by viral thymidine kinase explains its low toxicity to uninfected host cells.

• B. Mitochondrial DNA polymerase is not responsible for the initial activation step.
• C. Acyclovir does not act by binding viral envelope glycoproteins.
• D. Acyclovir acts on viral DNA polymerase, not RNA-dependent RNA polymerase.

Chloroquine has a strong affinity for melanin and accumulates in melanin-rich tissues such as the retinal pigment epithelium with long-term use. This cumulative, dose-dependent deposition damages photoreceptors and retinal pigment epithelium, producing the characteristic 'bull's eye' maculopathy with paracentral scotomas and eventual loss of central vision. Because the damage is largely irreversible, patients on long-term therapy require periodic ophthalmologic screening with visual field testing and optical coherence tomography. The finding described is classic bull's eye maculopathy, not a vascular or lens abnormality.

• A. The toxicity affects the retina, not acute optic nerve demyelination.
• C. Chloroquine retinopathy involves the macula, not lens opacification.
• D. Chloroquine retinopathy is due to drug accumulation in pigmented tissue, not an immune vasculitic process.

Primaquine is the only widely used drug active against the hepatic hypnozoite stage of P. vivax and P. ovale, and it is given after chloroquine therapy to prevent relapse. Primaquine causes oxidative damage to red blood cells and can precipitate severe hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, G6PD screening is mandatory before starting primaquine, and the dose or duration is adjusted based on the degree of deficiency per national malaria treatment guidelines. Chloroquine remains first-line for the blood stage of chloroquine-sensitive P. vivax.

• B. Coombs test is used to detect autoimmune hemolysis, not relevant to primaquine screening.
• C. Ceruloplasmin is used to screen for Wilson disease, unrelated to antimalarial therapy.
• D. Creatine kinase is relevant to statin-induced myopathy, not primaquine use.

Albendazole binds to beta-tubulin of susceptible helminths, inhibiting microtubule polymerization and thereby impairing glucose uptake and cytoplasmic microtubular function, leading to parasite immobilization and death. It is a broad-spectrum anthelmintic effective against roundworms, hookworms, whipworms, and pinworms such as Enterobius vermicularis, and is also used in cysticercosis and hydatid disease. It is typically given as a single or short-course oral dose depending on the parasite. Its broad activity against intestinal nematodes makes it the preferred drug for common soil-transmitted helminth infections in national deworming programmes.

• A. Praziquantel acts on calcium channels of trematodes and cestodes, not on beta-tubulin.
• B. Diethylcarbamazine is used for filarial infections and acts on microfilariae, not by binding beta-tubulin.
• D. Ivermectin acts on glutamate-gated chloride channels in nematodes and is used for strongyloidiasis and scabies.

ACE inhibitors block the enzyme that degrades bradykinin, leading to its accumulation in tissues, which is responsible for the characteristic dry cough and angioedema seen with this class. ACE inhibitors also reduce aldosterone secretion by blocking angiotensin II formation, which can cause hyperkalemia, especially in patients with renal impairment or diabetes. These drugs are contraindicated in pregnancy because they can cause fetal renal damage, oligohydramnios, and skull ossification defects. The cough typically resolves on discontinuation and switching to an angiotensin receptor blocker, which does not affect bradykinin metabolism.

• A. ACE inhibitors do not act on beta-2 receptors; this mechanism describes beta-blocker-induced bronchospasm.
• C. ACE inhibitors reduce, not increase, angiotensin II levels, so this is not the mechanism.
• D. The cough is due to bradykinin accumulation, not histamine-mediated mast cell degranulation.

Hypokalemia increases myocardial sensitivity to digoxin by enhancing its binding to the Na-K-ATPase pump, precipitating toxicity even at therapeutic digoxin levels, and loop diuretics are a common precipitating cause through potassium wasting. The visual disturbance with yellow-green halos (xanthopsia) and ventricular ectopy are classic features of digoxin toxicity. Digoxin immune Fab, composed of antidigoxin antibody fragments, binds free digoxin and rapidly reverses toxicity, and is indicated for life-threatening arrhythmias due to digoxin overdose. Correcting hypokalemia is also important, but the specific antidote for the cardiac toxicity is digoxin immune Fab.

• A. Cholestyramine reduces enterohepatic recirculation of digoxin but is not the first-line specific antidote for acute life-threatening toxicity.
• C. Calcium gluconate can worsen digoxin toxicity by further increasing intracellular calcium and is avoided.
• D. Atropine is used for symptomatic bradyarrhythmias, not the specific antidote for digoxin toxicity.

Statins can cause dose-dependent myopathy, which can progress to rhabdomyolysis with markedly elevated creatine kinase and myoglobinuria. Fibrates, particularly gemfibrozil, inhibit glucuronidation of statins and interfere with hepatic uptake transporters (OATP1B1), raising plasma statin concentrations and substantially increasing the risk of myopathy and rhabdomyolysis. This interaction is well documented and is less pronounced with fenofibrate compared to gemfibrozil. Patients on this combination should be monitored closely for muscle symptoms and creatine kinase elevation, and the combination is generally avoided when possible.

• A. Protein binding displacement is not the primary mechanism of this interaction.
• C. Gemfibrozil does not induce CYP3A4; its interaction is through glucuronidation and transporter inhibition, which raises rather than lowers statin levels.
• D. Enhanced renal tubular reabsorption is not the mechanism involved in this interaction.

Verapamil is a non-dihydropyridine calcium channel blocker with prominent effects on cardiac conduction tissue and smooth muscle of the gut. It slows conduction through the AV node, prolonging the PR interval and predisposing to AV block, and relaxes intestinal smooth muscle, causing constipation, its most common side effect. Dihydropyridines like amlodipine and nifedipine act mainly on vascular smooth muscle and have minimal effect on the AV node. Hydralazine is a direct vasodilator with no AV nodal or anticholinergic-type bowel effect.

• A. A dihydropyridine CCB with mainly vascular selectivity; it does not typically cause AV block or significant constipation.
• B. A direct arteriolar vasodilator used in hypertension; it causes reflex tachycardia, not AV block or constipation.
• D. Also a dihydropyridine; causes reflex tachycardia and flushing rather than AV block or constipation.

Unfractionated heparin acts via antithrombin III to inhibit thrombin (factor IIa) and factor Xa, primarily affecting the intrinsic pathway. Its anticoagulant effect is monitored using the activated partial thromboplastin time (aPTT), with a therapeutic target of about 1.5 to 2.5 times the control value. Prothrombin time/INR is used to monitor warfarin, which affects the extrinsic pathway via vitamin K-dependent factors. Bleeding time assesses platelet function, and platelet count is monitored separately to detect heparin-induced thrombocytopenia, not to adjust dosing.

• A. Platelet count is monitored to detect heparin-induced thrombocytopenia but does not guide heparin dosing.
• B. This test monitors warfarin therapy, which inhibits vitamin K-dependent clotting factors, not heparin.
• C. This test evaluates platelet plug formation and vascular integrity, not the intrinsic coagulation pathway affected by heparin.

Metformin primarily reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity and glucose uptake, without directly stimulating insulin secretion. It is renally excreted unchanged, and in significant renal impairment it can accumulate and impair hepatic lactate clearance, precipitating life-threatening lactic acidosis. For this reason, metformin is contraindicated when eGFR falls below approximately 30 mL/min/1.73 m². Glimepiride, pioglitazone, and acarbose do not carry this specific risk of lactic acidosis and act through entirely different mechanisms.

• B. Acarbose delays carbohydrate absorption in the gut and causes gastrointestinal side effects, not lactic acidosis.
• C. Pioglitazone improves insulin sensitivity via PPAR-gamma but is associated with fluid retention and heart failure, not lactic acidosis.
• D. Glimepiride is a sulfonylurea that stimulates insulin release; it carries a risk of hypoglycemia in renal impairment, not lactic acidosis.

Sulfonylureas such as glibenclamide bind to the SUR1 subunit of ATP-sensitive potassium channels on pancreatic beta cells, closing these channels and causing membrane depolarization, calcium influx, and insulin release regardless of ambient glucose concentration. This glucose-independent insulin secretion is why sulfonylureas, particularly long-acting ones like glibenclamide, carry a significant risk of severe and prolonged hypoglycemia, especially in elderly patients or those with renal impairment. Metformin does not stimulate insulin release and rarely causes hypoglycemia alone. Sitagliptin, a DPP-4 inhibitor, and empagliflozin, an SGLT2 inhibitor, both have low intrinsic hypoglycemia risk because their glucose-lowering effects are glucose-dependent.

• A. Metformin acts independently of insulin secretion and does not cause significant hypoglycemia as monotherapy.
• C. Empagliflozin promotes urinary glucose excretion independent of insulin and has a low risk of causing hypoglycemia.
• D. Sitagliptin potentiates glucose-dependent insulin release via incretin pathways and carries a low risk of hypoglycemia.

Prolonged corticosteroid therapy suppresses the hypothalamic-pituitary-adrenal (HPA) axis by negative feedback, reducing endogenous cortisol production. Abrupt discontinuation after prolonged use can precipitate acute adrenal insufficiency, presenting with hypotension, weakness, and shock. Gradual tapering allows the HPA axis to recover function progressively and prevents this withdrawal crisis. Tapering schedules are individualized based on dose and duration of prior therapy.

• A. A one-week switch does not allow adequate time for HPA axis recovery.
• B. Abrupt cessation after months of therapy risks acute adrenal crisis due to HPA axis suppression.
• D. A single stress dose does not address the need for gradual axis recovery and risks insufficiency once stopped.

Levothyroxine should be taken on an empty stomach, preferably 30-60 minutes before breakfast, because food, coffee, and calcium or iron supplements reduce its intestinal absorption. The serum TSH level is the most sensitive and reliable marker for titrating levothyroxine dose in primary hypothyroidism, since it reflects the pituitary response to circulating thyroid hormone. After starting or adjusting the dose, TSH is rechecked every 4-6 weeks until a stable euthyroid state is achieved, then monitored every 6-12 months. T3 and free T4 fluctuate more and are not used for routine dose titration.

• B. Food reduces levothyroxine absorption, and T3 is not the preferred monitoring parameter.
• C. Calcium impairs levothyroxine absorption, and free T4 is not the preferred monitoring parameter.
• D. Food impairs absorption and TSH changes too slowly to be checked daily.

Methotrexate inhibits dihydrofolate reductase, blocking conversion of dihydrofolate to tetrahydrofolate, which is required for purine and thymidylate synthesis and ultimately DNA synthesis. Folinic acid (leucovorin) is the reduced, active form of folate that bypasses the dihydrofolate reductase block, allowing normal cells to resume nucleotide synthesis while the tumor cells, which have already taken up high intracellular methotrexate, remain preferentially affected. This leucovorin rescue reduces methotrexate-induced bone marrow suppression and mucositis without significantly compromising its antileukemic effect. Folic acid cannot be used because it requires dihydrofolate reductase for activation, the very enzyme that is inhibited.

• A. Folic acid requires reduction by dihydrofolate reductase, the enzyme blocked by methotrexate, so it is ineffective as rescue therapy.
• C. Pyridoxine is used in isoniazid toxicity, not methotrexate rescue.
• D. Vitamin B12 has no role in reversing methotrexate's antifolate toxicity.

Vincristine is well known for causing dose-limiting peripheral neuropathy, including sensory disturbances, areflexia, and even autonomic dysfunction, due to its interference with axonal microtubule-dependent transport. Vinblastine, in contrast, has relatively mild neurotoxicity but causes more pronounced bone marrow suppression, making myelosuppression its dose-limiting toxicity. Both drugs act by binding tubulin and inhibiting microtubule polymerization, which arrests cells in metaphase, but their toxicity profiles differ, which is clinically useful in choosing between them based on a patient's bone marrow reserve or neurological status.

• B. Paclitaxel is a taxane, not a vinca alkaloid, and is not the paired drug in this classic comparison.
• C. Doxorubicin causes cardiotoxicity, not primarily myelosuppression as its most distinguishing feature in this comparison.
• D. This reverses the classic toxicity profiles of the two drugs.

Cisplatin causes dose-dependent nephrotoxicity through accumulation in proximal renal tubular cells, leading to tubular necrosis, and it can also cause ototoxicity through damage to cochlear hair cells. Vigorous intravenous hydration with normal saline before, during, and after cisplatin infusion maintains high urine output, which dilutes the drug in the tubules and reduces its nephrotoxic effect. Fluid restriction would worsen renal exposure to the drug. Aminoglycosides are nephrotoxic and ototoxic themselves and would worsen rather than protect against cisplatin toxicity.

• A. Fluid restriction increases drug concentration in the renal tubules and worsens nephrotoxicity.
• B. Aminoglycosides add to nephrotoxicity and ototoxicity rather than protecting against it.
• D. Urine alkalinization is used for methotrexate-induced crystal nephropathy, not cisplatin nephrotoxicity.

Doxorubicin causes cardiotoxicity through generation of free radicals and lipid peroxidation in cardiac myocytes, leading to a cumulative, dose-dependent dilated cardiomyopathy that can present as irreversible congestive heart failure. Because this toxicity correlates with total cumulative dose, left ventricular ejection fraction is monitored serially using echocardiography before and during treatment, and the drug is stopped if ejection fraction falls significantly or a cumulative dose threshold is approached. This cardiomyopathy is distinct from acute arrhythmic or pericardial effects and can manifest months to years after therapy, so monitoring continues both during and after treatment, not only afterward.

• A. Cardiotoxicity can occur during therapy as well, so monitoring only after completion would miss early changes requiring dose adjustment.
• B. Pericarditis is not the characteristic cardiotoxicity associated with doxorubicin.
• D. Acute arrhythmia is not the dose-limiting or primary toxicity of concern with doxorubicin.